Group One Trading
BBIO icon

Group One Trading’s BridgeBio Pharma BBIO Stock Holding History

Group One Trading’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4M Sell
53,800
-220,100
-80% -$16M 0.01% 1477
2025
Q4 		$21M Sell
273,900
-19,400
-7% -$1.27M 0.04% 521
2025
Q3 		$15.2M Sell
293,300
-26,500
-8% -$1.29M 0.03% 648
2025
Q2 		$13.8M Sell
319,800
-165,500
-34% -$6.02M 0.03% 619
2025
Q1 		$16.8M Sell
485,300
-334,500
-41% -$11.3M 0.05% 379
2024
Q4 		$22.5M Buy
819,800
+135,200
+20% +$3.49M 0.05% 337
2024
Q3 		$17.4M Buy
684,600
+75,400
+12% +$1.98M 0.05% 329
2024
Q2 		$15.4M Buy
609,200
+55,000
+10% +$1.5M 0.06% 278
2024
Q1 		$17.1M Buy
554,200
+88,300
+19% +$3M 0.07% 232
2023
Q4 		$18.8M Buy
465,900
+76,400
+20% +$2.29M 0.05% 373
2023
Q3 		$10.3M Buy
389,500
+7,600
+2% +$216K 0.03% 519
2023
Q2 		$6.57M Buy
381,900
+166,700
+77% +$2.51M 0.02% 766
2023
Q1 		$3.57M Buy
215,200
+179,400
+501% +$2.09M 0.01% 1060
2022
Q4 		$273K Sell
35,800
-97,100
-73% -$930K ﹤0.01% 3590
2022
Q3 		$1.32M Buy
132,900
+33,100
+33% +$344K ﹤0.01% 2287
2022
Q2 		$906K Sell
99,800
-60,400
-38% -$505K ﹤0.01% 2851
2022
Q1 		$1.63M Sell
160,200
-177,500
-53% -$1.82M ﹤0.01% 2606
2021
Q4 		$5.63M Buy
337,700
+320,600
+1,875% +$13.6M ﹤0.01% 1594
2021
Q3 		$801K Buy
17,100
+3,900
+30% +$209K ﹤0.01% 3655
2021
Q2 		$805K Sell
13,200
-24,900
-65% -$1.42M ﹤0.01% 3655
2021
Q1 		$2.35M Sell
38,100
-10,000
-21% -$654K ﹤0.01% 2288
2020
Q4 		$3.42M Buy
48,100
+17,200
+56% +$830K 0.01% 1593
2020
Q3 		$1.16M Sell
30,900
-75,000
-71% -$2.36M ﹤0.01% 2061
2020
Q2 		$3.45M Buy
105,900
+75,700
+251% +$2.31M 0.02% 1058
2020
Q1 		$876K Buy
+30,200
New +$936K 0.01% 1621

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading's BBIO Position: Q4 2025 in Review

Group One Trading sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 33,537 shares — an estimated $2.2M sold.

Group One Trading first reported a position in BBIO in Q4 2021 and held it in 11 quarters. The position peaked at $6.4M in Q4 2024. 432 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Group One Trading reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 33,537 BridgeBio Pharma shares in Q4 2025, an estimated $2.2M.
  • Group One Trading first reported a position in BridgeBio Pharma in Q4 2021 and held it in 11 quarters.
  • Group One Trading's BridgeBio Pharma position peaked at $6.4M in Q4 2024.
  • 432 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.